This was a single-institution, single-arm, non-therapeutic, interventional trial of 166 men with biopsy-confirmed prostate cancer enrolled between 2014–2020. Patients were placed on a trial-mandated AS protocol including yearly multiparametric MRI, prostate biopsy, and 4Kscore followed for 48 months after diagnosis.
Home Newsletters Evaluating 4Kscore’s Role in Predicting Progression on Active Surveillance for Prostate Cancer...